Oral administration of the vasopressin V2-receptor antagonist tolvaptan is safe and effective for the treatment of chronic hyponatremia in the long term, according to the results of the SALTWATER ...

Researchers from Gedeon Richter plc have reported the discovery of novel dual vasopressin V1A/V2 antagonist drug candidates for the potential treatment of hyponatremia.

Many studies have focused on the role of arginine vasopressin (AVP ... repeated intracerebroventricular (i.c.v.) injections of antagonists to the AVP-V1a receptor (AVPR) or of antagonists to ...

The drug is a vasopressin 1a (V1a) receptor antagonist, and evidence from human and animal studies suggest that the V1a receptor has a role in mediating and modulating key social behaviours ...

Tolvaptan is a vasopressin receptor antagonist. Vasopressin (a.k.a. ADH or antidiuretic hormone) helps to regulate water retention by absorbing water in the collecting ducts of the nephron.

HMNC Brain Health (HMNC) has completed the subject randomisation in its placebo-controlled Phase IIb OLIVE trial of a ...

Details: Randomized, double-blind, placebo-controlled trial involving 338 outpatients with MDD, conducted over an 8-week monotherapy period (250mg BID). Initial results from the OLIVE trial are ...

It was in this setting that tolvaptan, a novel vasopressin antagonist, was examined in the EVEREST trial. Disappointingly, there was no long-term mortality benefit; however, improvements in weight ...

To our knowledge, this is the largest case report of vasopressin use in the setting of PPHN. We found that addition of low-dose IV vasopressin was followed by improvement in oxygenation with a ...